Cargando…

Irreversible Electroporation Treatment With Intraoperative Biliary Stenting for Unresectable Perihilar Cholangiocarcinoma: A Pilot Study

BACKGROUND: Treating perihilar cholangiocarcinoma (PHCC) is particularly difficult due to the fact that it is usually in an advanced stage at the time of diagnosis. Irreversible electroporation treatment (IRE) involves the local administration of a high-voltage electric current to target lesions wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Po-Chih, Chen, Yan-Jun, Li, Xiao-Yong, Hsiao, Chih-Yang, Cheng, Bing-Bing, Gao, Yu, Zhou, Bai-Zhong, Chen, Sheng-Yang, Hu, Shui-Quan, Zeng, Quan, Huang, Kai-Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278819/
https://www.ncbi.nlm.nih.gov/pubmed/34277454
http://dx.doi.org/10.3389/fonc.2021.710536
_version_ 1783722338613723136
author Yang, Po-Chih
Chen, Yan-Jun
Li, Xiao-Yong
Hsiao, Chih-Yang
Cheng, Bing-Bing
Gao, Yu
Zhou, Bai-Zhong
Chen, Sheng-Yang
Hu, Shui-Quan
Zeng, Quan
Huang, Kai-Wen
author_facet Yang, Po-Chih
Chen, Yan-Jun
Li, Xiao-Yong
Hsiao, Chih-Yang
Cheng, Bing-Bing
Gao, Yu
Zhou, Bai-Zhong
Chen, Sheng-Yang
Hu, Shui-Quan
Zeng, Quan
Huang, Kai-Wen
author_sort Yang, Po-Chih
collection PubMed
description BACKGROUND: Treating perihilar cholangiocarcinoma (PHCC) is particularly difficult due to the fact that it is usually in an advanced stage at the time of diagnosis. Irreversible electroporation treatment (IRE) involves the local administration of a high-voltage electric current to target lesions without causing damage to surrounding structures. This study investigated the safety and efficacy of using IRE in conjunction with intraoperative biliary stent placement in cases of unresectable PHCC. METHODS: This study enrolled 17 patients with unresectable Bismuth type III/IV PHCC who underwent IRE in conjunction with intraoperative biliary stent placement (laparotomic) in two medical centers in Asia between June 2015 and July 2018. Analysis focused on the perioperative clinical course, the efficacy of biliary decompression, and outcomes (survival). RESULTS: Mean total serum bilirubin levels (mg/dL) on postoperative day (POD) 7, POD30, and POD90 were significantly lower than before IRE (respectively 3.46 vs 4.54, p=0.007; 1.21 vs 4.54, p<0.001; 1.99 vs 4.54, p<0.001). Mean serum carbohydrate antigen 19-9 (CA19-9, U/ml) levels were significantly higher on POD3 than before the operation (518.8 vs 372.4, p=0.001) and significantly lower on POD30 and POD90 (respectively 113.7 vs 372.4, p<0.001; 63.9 vs 372.4, p<0.001). No cases of Clavien-Dindo grade III/IV adverse events or mortality occurred within 90 days post-op. The median progression-free survival was 21.5 months, and the median overall survival was 27.9 months. All individuals who survived for at least one year did so without the need to carry percutaneous biliary drainage (PTBD) tubes. CONCLUSIONS: It appears that IRE treatment in conjunction with intraoperative biliary stent placement is a safe and effective approach to treating unresectable PHCC. The decompression of biliary obstruction without the need for PTBD tubes is also expected to improve the quality of life of patients.
format Online
Article
Text
id pubmed-8278819
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82788192021-07-15 Irreversible Electroporation Treatment With Intraoperative Biliary Stenting for Unresectable Perihilar Cholangiocarcinoma: A Pilot Study Yang, Po-Chih Chen, Yan-Jun Li, Xiao-Yong Hsiao, Chih-Yang Cheng, Bing-Bing Gao, Yu Zhou, Bai-Zhong Chen, Sheng-Yang Hu, Shui-Quan Zeng, Quan Huang, Kai-Wen Front Oncol Oncology BACKGROUND: Treating perihilar cholangiocarcinoma (PHCC) is particularly difficult due to the fact that it is usually in an advanced stage at the time of diagnosis. Irreversible electroporation treatment (IRE) involves the local administration of a high-voltage electric current to target lesions without causing damage to surrounding structures. This study investigated the safety and efficacy of using IRE in conjunction with intraoperative biliary stent placement in cases of unresectable PHCC. METHODS: This study enrolled 17 patients with unresectable Bismuth type III/IV PHCC who underwent IRE in conjunction with intraoperative biliary stent placement (laparotomic) in two medical centers in Asia between June 2015 and July 2018. Analysis focused on the perioperative clinical course, the efficacy of biliary decompression, and outcomes (survival). RESULTS: Mean total serum bilirubin levels (mg/dL) on postoperative day (POD) 7, POD30, and POD90 were significantly lower than before IRE (respectively 3.46 vs 4.54, p=0.007; 1.21 vs 4.54, p<0.001; 1.99 vs 4.54, p<0.001). Mean serum carbohydrate antigen 19-9 (CA19-9, U/ml) levels were significantly higher on POD3 than before the operation (518.8 vs 372.4, p=0.001) and significantly lower on POD30 and POD90 (respectively 113.7 vs 372.4, p<0.001; 63.9 vs 372.4, p<0.001). No cases of Clavien-Dindo grade III/IV adverse events or mortality occurred within 90 days post-op. The median progression-free survival was 21.5 months, and the median overall survival was 27.9 months. All individuals who survived for at least one year did so without the need to carry percutaneous biliary drainage (PTBD) tubes. CONCLUSIONS: It appears that IRE treatment in conjunction with intraoperative biliary stent placement is a safe and effective approach to treating unresectable PHCC. The decompression of biliary obstruction without the need for PTBD tubes is also expected to improve the quality of life of patients. Frontiers Media S.A. 2021-06-30 /pmc/articles/PMC8278819/ /pubmed/34277454 http://dx.doi.org/10.3389/fonc.2021.710536 Text en Copyright © 2021 Yang, Chen, Li, Hsiao, Cheng, Gao, Zhou, Chen, Hu, Zeng and Huang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Yang, Po-Chih
Chen, Yan-Jun
Li, Xiao-Yong
Hsiao, Chih-Yang
Cheng, Bing-Bing
Gao, Yu
Zhou, Bai-Zhong
Chen, Sheng-Yang
Hu, Shui-Quan
Zeng, Quan
Huang, Kai-Wen
Irreversible Electroporation Treatment With Intraoperative Biliary Stenting for Unresectable Perihilar Cholangiocarcinoma: A Pilot Study
title Irreversible Electroporation Treatment With Intraoperative Biliary Stenting for Unresectable Perihilar Cholangiocarcinoma: A Pilot Study
title_full Irreversible Electroporation Treatment With Intraoperative Biliary Stenting for Unresectable Perihilar Cholangiocarcinoma: A Pilot Study
title_fullStr Irreversible Electroporation Treatment With Intraoperative Biliary Stenting for Unresectable Perihilar Cholangiocarcinoma: A Pilot Study
title_full_unstemmed Irreversible Electroporation Treatment With Intraoperative Biliary Stenting for Unresectable Perihilar Cholangiocarcinoma: A Pilot Study
title_short Irreversible Electroporation Treatment With Intraoperative Biliary Stenting for Unresectable Perihilar Cholangiocarcinoma: A Pilot Study
title_sort irreversible electroporation treatment with intraoperative biliary stenting for unresectable perihilar cholangiocarcinoma: a pilot study
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278819/
https://www.ncbi.nlm.nih.gov/pubmed/34277454
http://dx.doi.org/10.3389/fonc.2021.710536
work_keys_str_mv AT yangpochih irreversibleelectroporationtreatmentwithintraoperativebiliarystentingforunresectableperihilarcholangiocarcinomaapilotstudy
AT chenyanjun irreversibleelectroporationtreatmentwithintraoperativebiliarystentingforunresectableperihilarcholangiocarcinomaapilotstudy
AT lixiaoyong irreversibleelectroporationtreatmentwithintraoperativebiliarystentingforunresectableperihilarcholangiocarcinomaapilotstudy
AT hsiaochihyang irreversibleelectroporationtreatmentwithintraoperativebiliarystentingforunresectableperihilarcholangiocarcinomaapilotstudy
AT chengbingbing irreversibleelectroporationtreatmentwithintraoperativebiliarystentingforunresectableperihilarcholangiocarcinomaapilotstudy
AT gaoyu irreversibleelectroporationtreatmentwithintraoperativebiliarystentingforunresectableperihilarcholangiocarcinomaapilotstudy
AT zhoubaizhong irreversibleelectroporationtreatmentwithintraoperativebiliarystentingforunresectableperihilarcholangiocarcinomaapilotstudy
AT chenshengyang irreversibleelectroporationtreatmentwithintraoperativebiliarystentingforunresectableperihilarcholangiocarcinomaapilotstudy
AT hushuiquan irreversibleelectroporationtreatmentwithintraoperativebiliarystentingforunresectableperihilarcholangiocarcinomaapilotstudy
AT zengquan irreversibleelectroporationtreatmentwithintraoperativebiliarystentingforunresectableperihilarcholangiocarcinomaapilotstudy
AT huangkaiwen irreversibleelectroporationtreatmentwithintraoperativebiliarystentingforunresectableperihilarcholangiocarcinomaapilotstudy